Nasal High Flow Reduces Dead Space

Winfried Möller, PhD1 2; Sheng Feng, MS3; Ulrike Domanski, PhD4; Karl-Josef Franke, MD4;
Gülnaz Celik, MS1 2; Peter Bartenstein, MD, Prof.5; Sven Becker, MD6; Gabriele Meyer, MD7;
Otmar Schmid, PhD1,2; Oliver Eickelberg, MD, Prof.1 2 8; Stanislav Tatkov, MD, PhD3;
Georg Nilius, MD,4

1Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung
Research, Max-Lebsche-Platz 31, 81377 Munich, Germany
2Institute of Lung Biology and Disease, Helmholtz Zentrum München – German Research
Center for Environmental Health, 85764 Neuherberg, Germany
3Fisher & Paykel Healthcare, Auckland, New Zealand
4HELIOS Klinik Hagen-Ambrock, Witten-Herdecke University, Hagen, Germany
5Department of Nuclear Medicine, LMU Medical Center Grosshadern, München, Germany
6Department of Otolaryngology, Head and Neck Surgery, LMU Medical Center Grosshadern,
München, Germany
7Department of Nuclear Medicine, Asklepios Fachkliniken München-Gauting, Gauting,
Germany
8University Hospital of the Ludwig Maximilian University (LMU),
81377 München, Germany

This manuscript has an online supplemental video file.

Corresponding author:
Dr. Winfried Möller
Helmholtz Zentrum München
Institute of Lung Biology and Disease / Comprehensive Pneumology Center
Ingolstädter Landstrasse 1
85764 Neuherberg, Germany
Phone +49 89 3187 1881
Email: moeller@helmholtz-muenchen.de

Copyright © 2016 by the American Physiological Society.
Nasal High Flow Reduces Dead Space

W. Möller, S. Feng, U. Domanski, K.-J. Franke, G. Celik, P. Bartenstein, S. Becker, G. Meyer, O. Schmid, O. Eickelberg, S. Tatkov, G. Nilius

ABSTRACT:
Recent studies show that nasal high flow (NHF) therapy can support ventilation in patients with acute or chronic respiratory disorders. Clearance of dead-space has been suggested as being the key mechanisms of respiratory support with NHF therapy. The hypothesis of this study was that NHF in a dose-dependent manner can clear dead space of the upper airways from expired air and decrease re-breathing.
The randomized cross-over study involved 10 volunteers using scintigraphy with $^{81m}$Krypton-gas ($^{81m}$Kr-gas) during a breath-holding maneuver with closed mouth and in three nasally breathing tracheotomized patients by volumetric capnography and oximetry through sampling $\text{CO}_2$ and $\text{O}_2$ in the trachea and measuring the inspired volume with inductance plethysmography following NHF rates of 15, 30 and 45 L/min.
The scintigraphy revealed a decrease in $^{81m}$Kr-gas clearance half-time with an increase of NHF in the nasal cavities ($cc = -0.55$, $p < 0.01$), pharynx ($cc = -0.41$, $p < 0.01$) and the trachea ($cc = -0.51$, $p < 0.01$). Clearance rates in nasal cavities derived from time constants and MRI-measured volumes were 40.6 (SD 12.3), 52.5 (SD 17.7) and 72.9 (SD 21.3) mL/s during NHF (15-30-45L/min). Measurement of inspired gases in the trachea showed an NHF-dependent decrease of inspired $\text{CO}_2$ that correlated with an increase of inspired $\text{O}_2$ ($cc = -0.77$, $p < 0.05$). NHF clears the upper airways from expired air, which reduces dead space by a decrease of re-breathing making ventilation more efficient. The dead-space clearance is flow and time-dependent and it may extend below the soft palate.

Part of the study has been registered at www.clinicaltrials.gov (NCT01509703).

Keywords: nasal high flow, upper airways, dead space, re-breathing, Krypton, respiratory support
New and Noteworthy

Clearance of expired air in upper airways by nasal high flow (NHF) can be extended below the soft palate and de facto causes a reduction of dead-space. Using scintigraphy the authors found a relationship between NHF, time and the clearance. Direct measurement of CO₂ and O₂ in the trachea confirmed a reduction of re-breathing, providing the actual data on inspired gases and this can be used for the assessment of other forms of respiratory support.
INTRODUCTION

Recent studies report that an open nasal cannula system that generates nasal high flow (NHF) with or without supplemental oxygen (O₂) can assist ventilation in patients with chronic respiratory failure, sleep disorders, hypoxemic patients after cardiothoracic surgery, and those with acute hypoxemic respiratory failure. In addition, the use of this form of respiratory support in pediatrics and in newborns has proven clinical benefits. Delivering a high flow of gas through the open nasal cannula to generate airway pressure has been tried in the past but developments in technology have now allowed efficiently heated and humidified respiratory gases to enable a wide range of flow rates from 2 L/min in preterm newborns to 60 L/min in adults.

A number of clinically relevant benefits have been associated with NHF therapy: reduction in respiratory rate, a decrease of minute ventilation during sleep, improved alveolar ventilation, a reduction in wasted ventilation, and the work of breathing, although how NHF produces these effects is not yet understood. A mechanistic study on healthy volunteers suggested two different ventilatory responses to NHF, one when awake and another during sleep. In this study it was speculated that the reduction of dead-space ventilation due to clearance of anatomical dead-space in the upper airways could be the principal driver for the reduction of minute ventilation during sleep, which may potentially lead to a reduction in the work of breathing. In a previous study using upper airway models the authors demonstrated the fast-occurring flow dependent clearance of nasal cavities by NHF. The dead-space clearance is difficult to study in vivo due to the complexity in quantifying the respiratory gases in the airways. However, many have proposed it to be the major physiological mechanism, which improves respiratory support and reduces arterial and tissue CO₂.

The aim of this study was to measure upper airway dead-space reduction during NHF therapy to test a hypothesis that NHF in a dose-dependent manner can clear dead space in the upper airways and decrease re-breathing.
Clearance of $^{81m}$Kr tracer gas from the upper airways by NHF was assessed in healthy volunteers using dynamic gamma camera imaging. Reduction of re-breathing was investigated in tracheotomized patients using volumetric capnography and oximetry by sampling gas from the trachea while the patients maintained nasal breathing during NHF therapy.

**METHODS**

**Study participants**

Ten healthy, non-smoking volunteers (age 55 +/- 14 years) participated in the tracer-gas scintigraphy study (Table 1). This part of the study was approved by the Ethics Committee of the Medical School of the Ludwig Maximilian University (Munich, Germany), and written consent was obtained from each subject.

In the second part, three male patients who did not require supplemental $O_2$ were included, each of whom had received long-time mechanical ventilation through a tracheostomy and then were admitted for weaning. Two of them had COPD (age 59 and 72 years), and the third patient was recovering from subarachnoid hemorrhage and pneumonia (age 72 years). This part of the study was approved by the Ethics Committee of Witten-Herdecke University, Germany, and registered under clinicaltrials.gov (NCT01509703).

**Nasal high flow (NHF)**

NHF rates of 15, 30 and 45 L/min without supplemental oxygen were delivered in a randomized order using the AIRVO™ blower-humidifier and the Optiflow™ nasal cannula (Fisher & Paykel Healthcare, New Zealand). In the scintigraphy study NHF was delivered for 30 s (during breath-holding). In the tracheotomized nasally-breathing patients NHF was delivered continuously for 10 min. Throughout all studies the mouth remained closed.

**Scintigraphy**

For these experiments the $^{81m}$Kr-gas was generated and a planar gamma camera was used for imaging, as described in detail earlier (18). The volunteers filled their upper airways with
$^{81}$mKr tracer gas through the nasal pillow, and the NHF cannula with the preset flow was inserted into the nose while the volunteer was holding their breath. $^{81}$mKr-gas activity-time profiles were assessed in five regions of interest (ROI): anterior nasal (Nasal1), posterior nasal (Nasal2), pharynx (space from the soft palate to the larynx), trachea and the upper lung (Figure 1A). $^{81}$mKr-gas clearance time constants and half-times were evaluated after correction with the natural $^{81}$mKr-gas decay ($T_{1/2} = 13$ s). Nasal clearance rates were evaluated as the ratio of nasal volume ($V_N$) and clearance time constant. Nasal volume, comprising the nasal cavity and the nasopharynx (excluding sinuses) was assessed using individual MRI imaging.

**Clearance of anatomical dead space in tracheotomized patients**

Tracheotomized patients were included in order to assess re-breathing of expired gas from the upper airways. When the weaning from invasive mechanical ventilation was completed the tracheostomy tube was replaced with a tracheostomy retainer (2). A custom-made probe was placed through the retainer to measure $O_2$, $CO_2$ and pressure profiles for synchronization with breathing (ADInstruments, New Zealand). Inspiratory volume was assessed with calibrated respiratory inductance plethysmography (RIP; Viasys Services, USA), as described in detail previously (12, 19).

The effect of NHF on the volume of inspired $O_2$ and $CO_2$ was analyzed for every breath. Inspired $O_2$ was calculated in the first 100 mL of inspired volume. Inspired $CO_2$ was calculated in the total inspired volume and in the first 100 mL. Arterial blood oxygen saturation ($SpO_2$) and transcutaneous $CO_2$ (Tosca, Radiometer, Denmark) were monitored throughout the study.

**Data analysis**

All data is presented as mean +/- standard deviation (SD). Differences between groups or application modes were assessed by a two-sided t-test using a significance level of $p < 0.05$. Pearson’s coefficient correlation (cc) analysis was then applied, to assess the correlation among the study variables.
RESULTS

81mKr-gas clearance in healthy volunteers

After filling the upper airways with 81mKr-gas the volunteer was holding his or her breath and the NHF cannula was attached to their nose; this caused immediate purging of the 81mKr-gas from the upper airways (Figure 1B and supplemental video). NHF caused rapid activity decay in the nasal cavity and, as shown in Figure 1B, the nasal cavity was cleared at 0.5 s after applying NHF at a rate of 45 L/min.

The half-times of 81mKr-gas clearance in nasal regions are shown in Table 2 and Figure 2A. For both the anterior (Nasal1) and the posterior (Nasal2) ROIs, there was a decrease in 81mKr-gas clearance half-time with an increase of NHF from 15 to 45 L/min (cc = -0.55, p < 0.01) in all subjects. Nasal1 ROI cleared faster compared to the Nasal2 (p < 0.01) and clearance half-times in both ROIs highly correlate (cc = 0.55, p < 0.01). There is no correlation between clearance half-times and individual nasal volumes VN derived from MRI scans. Using the time constants for both ROIs and VN, the clearance rate in the nasal cavities was calculated: 40.6 (SD 12.3), 52.5 (SD 17.7) and 72.9 (SD 21.3) mL/s during NHF of 15, 30 and 45 L/min, respectively. This demonstrates that there is a significant correlation between clearance rate and NHF (cc = 0.61, p < 0.01).

In the lower compartments beyond the soft palate, 81mKr-gas clearance was also NHF dependent but slower (pharynx: cc = -0.41, p < 0.01; trachea: cc = -0.51, p < 0.01; Table 2 and Figure 2B) and in some experiments only natural 81mKr-gas decay was recorded. Pharyngeal and tracheal clearance half-times correlated with the nasal half times (cc = 0.4, p < 0.05). There was no detected 81mKr-gas clearance in the lung ROI.

Re-breathing of expired air during NHF therapy in tracheotomized patients

An example of a single-breath analysis of inspired CO2 and O2 at baseline and during an NHF rate of 45 L/min is presented in Figures 3A and 3B. A summary of the effects of NHF on inspired CO2 and O2 in the first 100 mL is shown in Figure 4. In all three patients studied, NHF led to a decrease of inspired CO2 and to an increase of inspired O2 in a flow-dependent manner (Figure 4A and 4B). Linear regression analyses between a change (Δ) of total inspired
O₂ versus CO₂ in the first 100 mL per breath are presented in Figure 4C. An NHF-induced decrease of inspired CO₂ correlates with an increase of inspired O₂ (cc = -0.767; r² = 0.59, p = 0.016). A ratio between inspired CO₂ in the first 100 mL of inspired volume to the total inspired CO₂ grouped by all baselines and NHF treatments is presented in Figure 4D. NHF resulted in a significantly higher ratio during NHF treatment relative to baseline ventilation (0.84 (SD 0.10) vs. 0.75 (SD 0.12); p < 0.01, paired t-test). Change of tidal volume, respiratory rate, minute ventilation as well as SpO₂ and tissue CO₂ throughout the study are presented in Table 3.

**DISCUSSION**

In the first part of the study, dead-space clearance by NHF therapy was analyzed in 10 healthy volunteers by the use of ⁸¹mKr-gas, a radioactive tracer gas and a gamma camera. The major findings in this investigation are the NHF-dependent reduction of radioactive tracer-gas clearance half-times in the upper airways with very fast removal of the tracer gas from the nasal cavities (half-times < 0.5 s at an NHF rate of 45 L/min) that confirmed the authors’ model study (18). Further in various volunteers significant ⁸¹mKr-gas clearance was detected in deeper compartments below the soft palate, which could be investigated only in vivo. Rates of NHF in the range of 15 to 45 L/min were used, which were also used previously (18) and which is common in clinical settings for adults. NHF rates up to 60 L/min were used in patients with acute respiratory failure (28), but cannot be well tolerated by some naïve healthy participants that were found during the preparation of the experiments. In the second part of the study, tracheal O₂ and CO₂ breathing profiles in three tracheotomized patients revealed an NHF-dependent increase of inspired O₂ and a decrease of inspired CO₂, which confirmed a reduction of re-breathing and supported a hypothesis that NHF reduces dead space.

The ⁸¹mKr-gas imaging has demonstrated very fast clearance of the tracer gas after the application of high flow through the nasal cannula. The clearance half-times were shorter in the anterior than in the posterior ROIs, demonstrating the direction of clearance, and they were inversely correlated with NHF. Most of the clearance took place in the nasal ROIs with half-times under 1.0 s (Figures 1B and 2A).
The clearance study was conducted during breath-holding. The effects of respiration on clearance were excluded in this research to avoid the effect of breathing and due to the technical restrictions. In several experiments there was no $^{81m}$Kr-gas clearance below the soft palate (see also Figure 2B). This could be induced voluntarily, since it has been shown that subjects can close their soft palate unintentionally during the breath-holding, but the mechanism of this reflex is not fully understood (10).

Clearance of $^{81m}$Kr-gas in the lower parts of conducting airways may be of lesser relevance due to very long half-times, as revealed; however, the fact that NHF can produce some clearance even in those deep compartments may suggest a potential increase of the NHF clearance efficiency with a presence of long end-expiratory pauses or opening of the mouth. In other words, clearance of the upper airways by NHF may not be limited by the volume of the nasal cavities.

The results of clearance from nasal cavities are very similar to experiments conducted in upper airway models (18). Faster clearance in the model study can be explained by the lack of restrictions in the reconstructed upper airways compared to those of the real human anatomy. Similar to the model experiments used during the current study, the clearance rate was assessed in the same two adjoining nasal ROIs and also showed a linear relationship with NHF. It is nearly doubled (from 40.6 (SD 12.3) to 72.9 (SD 21.3) mL/s) with an increase of NHF from a rate of 15 to 45 L/min.

Clearance of tracer gas in the upper airways was further confirmed in tracheal CO$_2$ and O$_2$ breathing profiles of three tracheotomized patients. The tracheal inhalation profiles plotted for one patient (see Figures 3A and 3B) show that an NHF rate of 45 L/min reduces the inspired CO$_2$ and increases the inspired O$_2$ compared to baseline. Profiles of inspired tracheal CO$_2$ and O$_2$ demonstrate that the maximum difference between the gases is positioned between the first 50 mL and 100 mL of the inspired volume. NHF resulted in a flow-related reduction of CO$_2$ re-breathing (Figure 4A) and an increase of O$_2$ in the inspired gas (Figure 4B) with a negative correlation ($cc = -0.767; n = 9, p < 0.05$), as further analyzed in Figures 4C and 4D.
At the end of expiration, conducting airways are filled with gas that typically contains approximately 5% of CO$_2$ and 16% of O$_2$ and at the beginning of inspiration the expired gas is re-inspired back into the lungs. NHF delivers fresh air into the upper airways through a pair of non-sealed cannulas, purging the expired gas outside the nasal cavity. There is very little CO$_2$ in ambient air (0.04%) and consequently CO$_2$ can be compared in a total inspired volume between the baseline and NHF. Inspired O$_2$ is greatly dependent on inspired tidal volume and in order to accurately measure a relatively small change of O$_2$, only a re-breathing portion has to be measured in the inspired volume. The authors chose the first 100 mL to measure a change of inspired CO$_2$ during NHF application. A smaller difference between the recorded decrease of inspired tracheal CO$_2$ and the increase of inspired tracheal O$_2$ can be explained by a calculation of inspired O$_2$ in the first 100 mL of inspired gas and the fact that gas was sampled from the trachea into the gas analyzer, prolonging the response time. Inspired CO$_2$ is presented in Figures 3A and 4A as a total rather than as the first 100 mL per breath, as with O$_2$, because of high clinical relevance.

The ratio of CO$_2$ in the first 100 mL of inspired air to the total inspired CO$_2$, as shown in Figure 4D, resulted in a significantly higher ratio during NHF relative to the baseline (ratio = 0.84 (SD 0.10) during NHF vs. 0.75 (SD 0.12) at baseline; p < 0.01, paired t-test). This can be explained by the clearance of expired gas in the upper airways that causes a reduction of the last portion of re-inspired CO$_2$ measured in the trachea, thereby enhancing the ratio. Therefore, when applying NHF, re-inspired CO$_2$ primarily results from the first 100 mL of the inspired air, making the difference between the volumes of inspired CO$_2$ smaller and shifting the ratio closer to 1.00. It can also be illustrated in Figure 3A, which shows most of CO$_2$ during NHF is measured within the first 100 mL and consequently increasing the ratio of CO$_2$ measured in 100 mL to CO$_2$ measured in the total inspired gas volume. The method of the ratio calculation can be recommended for future studies as it is informative and may be used without calibration of inspired volume.

Data on ventilation during the study (Table 3) shows a rather small amount of tidal volume measured with RIP in all three patients. RIP was calibrated with a pneumotachograph before and after the experiment and showed very small drift between calibrations, confirming the
robustness of the data. Nevertheless, tidal volumes smaller than 250 to 300 mL with normal respiratory rate may suggest some inaccuracy of the method, which could affect volumes of calculated inspired O$_2$ and CO$_2$ and lead to an underestimation of the parameters. It is interesting to note that in two experiments minute ventilation was markedly reduced during NHF while the respiratory rate was within normal values (range 10.6 to 15.0 min$^{-1}$) and there was no change in blood gases. Reduction of minute ventilation through a decrease of tidal volume may indicate a reduction in the work of breathing without a change in blood gases, which could remain clinically undetected because tidal volume is not measured routinely during NHF therapy. Variability in the ventilation parameters shows that the effect of NHF on ventilation in patients has to be investigated in the homogenous groups. The presence of a probe in the trachea may also affect the breathing pattern and is preferably to be excluded in such studies.

**Physiological and clinical implications**

A decrease of re-breathing of CO$_2$ by approximately 1 mL to 3 mL per breath calculated from the inspired volume with an end-tidal concentration of 5% and a similar increase of inspired O$_2$ correspond to a reduction of dead space by 20 to 60 mL following a rise of the NHF rate from 15 to 45 L/min. This indicates an agreement of data between the scintigraphy part of the study in volunteers and the measurements of inspired gases in the tracheotomized patients. The scintigraphy during breath-holding showed the tracer-gas clearance at different levels of conducting airways in relation to NHF rates and time. Measurement of CO$_2$ and O$_2$ in the trachea during respiration confirmed the NHF-dependent decrease of re-breathing of expired air, which is eventually a reduction of dead space.

The reduction of dead space by NHF may increase alveolar volume if tidal volume remains the same. It may also slow down the respiratory rate or reduce tidal volume and minute ventilation, as has been observed in this study and also as previously reported in healthy subjects during sleep (19). Reduction of the respiratory rate is the most frequently described respiratory parameter associated with NHF therapy in adults and children (1, 16, 26) and it is also reported to be a simple and informative predictor of potentially serious clinical events (3). It might be speculated that the reduction of respiratory rate by NHF can be more substantial in patients with an increased respiratory rate. In this study the authors observed
very small reduction of the respiratory rate, which was within normal limits, but the small
sample size and the study design did not allow for any definitive conclusion. Reduction of
dead space may also affect gas exchange: a reduction of arterial CO₂ (1)(20) and an increase
of oxygenation (7, 20) by NHF were shown, although these effects were not evident in this
study, probably, because the NHF application times (10 min) were too short.

The ratio of dead space to tidal volume increases during shallow breathing or when the total
physiological dead space is raised due to an increase of alveolar dead space in conditions like
emphysema, pulmonary embolism or ARDS (9, 13); this requires an increase of breathing
frequency to maintain the same level of alveolar ventilation. For the above-mentioned
conditions a small reduction of dead space would lead to a significant improvement in gas
exchange resulting in the reduction of minute ventilation, which would normalize blood gas
parameters or both.

Physiological effects and clinical outcomes related to the reduction of dead space during
NHF may also be affected by the generated positive airway pressure that can modify
breathing patterns and change the efficiency of the dead space clearance. Based on the data
from the scintigraphy it is also likely that the efficiency of dead-space clearance can
potentially be increased with the reduction of respiratory rate.

Patients with obstructive and restrictive respiratory disease, as well as stable patients and
those in respiratory distress or undergoing respiratory failure, are expected to respond
differently to the reduction of dead space by NHF. Nevertheless, an improvement of gas
exchange resulting in a reduction of minute ventilation and/or the normalizing of blood
gases can be anticipated during NHF therapy.

**Strengths and limitations**

There are two key strengths in this current study. The first is the evaluation of dead-space
clearance without a breathing component, which is also a limitation and is outlined below.
The level of clearance is most efficient in the nasal cavities but may extend below the soft
palate; however, this has to be interpreted with caution. The data adds weight to the
argument that the respiratory support effects of NHF treatment are dependent not only on
the NHF rate but also on time; the longer the time during which NHF produces clearance at
the end of expiration, the more significant clearance can be expected. The second key
strength of the study is that the reduction of re-breathing by NHF was shown via a change of
actual gas composition in the inspired air. A correlation between the change of inspired
volumes of CO₂ and O₂ confirms the validity of the measurements. Elimination of CO₂ is of
primary interest, as a fraction of removed CO₂ from the expired gas is relatively higher than
the added fraction of O₂ and it is clinically relevant in hypercapnic patients. A role of
additional O₂ as a result of dead-space clearance in normo- and hypoxemic patients is yet to
be determined.

There are limitations to this study, however. The main drawback is that only static clearance
rates in the absence of breathing were quantified in the scintigraphy part. There were three
reasons to justify the design. First, ⁸¹Kr-gas has a short lifetime (13 s) and it is a technical
restriction to visualize a fast-decaying radioactive tracer gas. Second, tidal breathing would
not allow studying the maximum clearance that can be potentially achieved by NHF.
Excluded in this study were investigations into the NHF clearance effects during a range of
tidal volumes, breathing patterns, opening the mouth, position of the soft palate, vocal
cords and the effects of changing the nasal prong size and position; these factors need to be
addressed separately in future study designs. Had the authors endeavored to include some
of these elements in the current study, they would have had to complicate the protocol
significantly and increase the number of patients in the group substantially, who would also
have needed to be homogeneous to allow adequate quantifications of individual responses.
The study of three tracheotomized patients was sufficient to demonstrate the NHF-
dependent reduction of re-breathing as a physical process – although a large sample size in a
controlled trial would be required for the analysis of the above-mentioned parameters,
physiological responses or clinical outcomes of NHF therapy, which need to be studied
separately. It is unlikely that an increase of a sample size in the study without a change of
the design would lead to a valid conclusion on the physiological and clinical effects of NHF
therapy as the effects will greatly depend on the baseline parameters and duration of the
therapy. Frequent change of NHF rates during a relatively short time is not a desirable study
design for assessment of awake, spontaneously-breathing patients where an individual
voluntary response may affect the results. Also, a maximum NHF rate of 45 L/min was used
in this study in order to repeat the same three flows investigated in a model study (18) and to limit the maximum radioactive daily exposure for the volunteers. In tracheotomized patients there was a risk of non-completion of the protocol should another NHF rate be added. Apart from the above, the authors could not exclude the fact that some patients would not tolerate higher NHF unless they are in respiratory distress.

In summary, this study has shown effective clearance of the tracer gas by NHF in the upper airways. The clearance is directly related to the NHF rate and time, demonstrating that expired air can be cleared even below the soft palate. The clearance of dead space leads to a reduction in re-breathing of expired air. It may reduce the volume of dead space and increase the alveolar volume, which can result in improvement of alveolar ventilation and gas exchange during NHF therapy.

GRANTS
The study was supported by research grants from Fisher & Paykel Healthcare, Auckland, New Zealand.

DISCLOSURES
WM received research grants from Pari GmbH, Germany, for studying nasal aerosolized drug delivery and from Fisher & Paykel Healthcare, New Zealand, for studying the role of nasal high flow in dead-space clearance. GN received research grants from Fisher & Paykel Healthcare, ResMed, Respironics Inc., Philips, Weimann and Heinen & Löwenstein. SF and ST are employees of Fisher & Paykel Healthcare, New Zealand. All other authors declare no conflicts of interest.

ACKNOWLEDGEMENTS
The authors would like to acknowledge G. Murray for development of a probe for tracheotomized patients.

AUTHOR CONTRIBUTIONS
WM, SF, UD, PB, OE, OS, ST and GN – conception and design of research;
WM, GC, SF, UD, KJF, GM and ST – performed experiments;
WM, GC, SF, UD, OS and ST – analyzed data;
WM, SF, UD, ST and GN – interpreted results of experiments;
WM, SF, ST and GN – drafted manuscript;
WM, SF, OS, ST and GN – edited and revised manuscript;
WM, GC, SF, UD, KJF, PB, GM, OE, OS, ST and GN – approved final version of manuscript.
REFERENCES

1. Bräunlich J, Beyer D, Mai D, Hammerschmidt S, Seyfarth HJ, and Wirtz H. Effects of Nasal High Flow on Ventilation in Volunteers, COPD and Idiopathic Pulmonary Fibrosis Patients. *Respiration* 85: 319-325, 2013.

2. Budweiser S, Baur T, Jörres RA, Kollert F, Pfeifer M, and Heinemann F. Predictors of Successful Decannulation Using a Tracheostomy Retainer in Patients with Prolonged Weaning and Persisting Respiratory Failure. *Respiration* 84: 469-476, 2012.

3. Cretikos MA, Bellomo R, Hillman K, Chen J, Finfer S, and Flabouris A. Respiratory rate: the neglected vital sign. *Med J Aust* 188: 657-659, 2008.

4. Dysart K, Miller TL, Wolfson MR, and Shaffer TH. Research in high flow therapy: Mechanisms of action. *Respir Med* 103: 1400-1405, 2009.

5. Fraser JF, Spooner AJ, Dunster KR, Anstey CM, and Corley A. Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised crossover trial. *Thorax* 71: 759-761, 2016.

6. Frat J-P, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, Prat G, Boulain T, Moraweic E, Cottereau A, Devaquet J, Nseir S, Razazi K, Mira J-P, Argaud L, Chakarian J-C, Ricard J-D, Wittebole X, Chevalier S, Herblaud A, Fartoukh M, Constantin J-M, Tonnelier J-M, Pierrot M, Mathonnet A, Béduneau G, Delétage-Métreau C, Richard J-CM, Brochard L, and Robert R. High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure. *N Engl J Med* 372: 2185-2196, 2015.

7. Frizzola M, Miller TL, Rodríguez ME, Zhu Y, Rojas J, Hesek A, Stump A, Shaffer TH, and Dysart K. High-flow nasal cannula: impact on oxygenation and ventilation in an acute lung injury model. *Pediatr Pulmonol* 46: 67-74, 2011.

8. Hutchings FA, Hilliard TN, and Davis PJ. Heated humidified high-flow nasal cannula therapy in children. *Arch Dis Child* 100: 571-575, 2015.

9. Kallet RH, Zhuo H, Liu KD, Calfee CS, and Matthay MA. The Association Between Physiologic Dead-Space Fraction and Mortality in Subjects With ARDS Enrolled in a Prospective Multi-Center Clinical Trial. *Respir Care* 59: 1611-1618, 2014.

10. Kharritonov SA, and Barnes PJ. Nasal contribution to exhaled nitric oxide during exhalation against resistance or during breath holding. *Thorax* 52: 540-544, 1997.

11. Lee JH, Rehder KJ, Williford L, Cheifetz IM, and Turner DA. Use of high flow nasal cannula in critically ill infants, children, and adults: a critical review of the literature. *Intensive Care Med* 39: 247-257, 2013.

12. Leino K, Nunes S, Valta P, and Takala J. Validation of a new respiratory inductive plethysmograph. *Acta Anaesthesiol Scand* 45: 104-111, 2001.

13. Lewis S, and Martin CJ. Characteristics of the washout dead space. *Respir Physiol* 36: 51-63, 1979.

14. Maggiore SM, Idone FA, Vaschetto R, Festa R, Cataldo A, Antonicelli F, Montini L, De Gaetano A, Navalesi P, and Antonelli M. Nasal High-Flow versus Venturi Mask Oxygen Therapy after Extubation. Effects on Oxygenation, Comfort, and Clinical Outcome. *Am J Respir Crit Care Med* 190: 282-288, 2014.

15. Manley BJ, Owen LS, Doyle LW, Andersen CC, Cartwright DW, Pritchard MA, Donath SM, and Davis PG. High-Flow Nasal Cannulae in Very Preterm Infants after Extubation. *N Engl J Med* 369: 1425-1433, 2013.
16. Mayfield S, Bogossian F, O'Malley L, and Schibler A. High-flow nasal cannula oxygen therapy for infants with bronchiolitis: Pilot study. *J Paediatr Child Health* 50: 373-378, 2014.

17. McGinley BM, Patil SP, Kirkness JP, Smith PL, Schwartz AR, and Schneider H. A Nasal Cannula Can Be Used to Treat Obstructive Sleep Apnea. *Am J Respir Crit Care Med* 176: 194-200, 2007.

18. Möller W, Celik G, Feng S, Bartenstein P, Meyer G, Eickelberg O, Schmid O, and Tatkov S. Nasal High Flow Clears Anatomical Dead Space in Upper Airway Models. *J Appl Physiol* 118: 1525-1532, 2015.

19. Mündel T, Feng S, Tatkov S, and Schneider H. Mechanisms of nasal high flow on ventilation during wakefulness and sleep. *J Appl Physiol* 114: 1058-1065, 2013.

20. Nilius G, Franke K-J, Domanski U, Rühle K-H, Kirkness J, and Schneider H. Effects of Nasal Insufflation on Arterial Gas Exchange and Breathing Pattern in Patients with Chronic Obstructive Pulmonary Disease and Hypercapnic Respiratory Failure. In: Respiratory Regulation - Clinical Advances, edited by Pokorski M Springer Netherlands, 2013, p. 27-34.

21. Nilius G, Wessendorf T, Maurer J, Strohs R, Patil SP, Schubert N, and Schneider H. Predictors for treating obstructive sleep apnea with an open nasal cannula system (transnasal insufflation). *CHEST Journal* 137: 521-528, 2010.

22. Ricard JD. High flow nasal oxygen in acute respiratory failure. *Minerva Anestesiol* 78: 836-841, 2012.

23. Sotello D, Rivás M, Mulkey Z, and Nugent K. High-Flow Nasal Cannula Oxygen in Adult Patients: A Narrative Review. *Am J Med Sci* 349: 179-185, 2015.

24. Spoletini G, Alotaibi M, Blasi F, and Hill NS. Heated humidified high-flow nasal oxygen in adults: Mechanisms of action and clinical implications. *Chest* 148: 253-261, 2015.

25. Stéphan F, Barrucand B, Petit P, and et al. High-flow nasal oxygen vs noninvasive positive airway pressure in hypoxemic patients after cardiothoracic surgery: A randomized clinical trial. *JAMA* 313: 2331-2339, 2015.

26. Sztrymf B, Messika J, Mayot T, Lenglet H, Dreyfuss D, and Ricard J-D. Impact of high-flow nasal cannula oxygen therapy on intensive care unit patients with acute respiratory failure: A prospective observational study. *J Crit Care* 27: 324.e329 - 324.e313, 2012.

27. Theilade D. Nasal CPAP employing a jet device for creating positive pressure. *Intensive Care Med* 4: 145-148, 1978.

28. Vargas F, Saint-Leger M, Boyer A, Bui NH, and Hilbert G. Physiologic Effects of High-Flow Nasal Cannula Oxygen in Critical Care Subjects. *Respir Care* 60: 1369-1376, 2015.
Table 1: Anthropometric data of 10 healthy volunteers participating in the study. NS – non-smokers, S – smokers, XS – ex-smokers, VDA – anatomical dead-space volume based on height (Hart MC, et al., J. Appl. Physiol. 1963; 18(3):519-522), VN – nasal volume corresponding to Nasal1 and Nasal2 ROIs derived from individual MRI scans.

|                          | Mean (SD) |
|--------------------------|-----------|
| Male/Female              | 7/3       |
| NS/S/XS                  | 7/0/3     |
| Age, Years               | 55 (14)   |
| Height, cm               | 175 (10)  |
| Weight, kg               | 74 (12)   |
| BMI, kg/m²               | 24 (6)    |
| VDA, mL                  | 152 (19)  |
| VN, mL                   | 42 (6)    |

Table 2: Half-times T₁/₂ of ⁸¹mKr-gas clearance (mean, standard deviation (SD)) in the anterior (Nasal1), posterior (Nasal 2) part of nasal cavity, in the pharynx and trachea region of interests (ROI) of healthy volunteers during 15, 30 and 45 L/min of nasal high flow (NHF). In all compartments half-times correlated with NHF (Nasal1: cc = -0.55, p < 0.01; Nasal2: cc = -0.57, p < 0.01; pharynx: cc = -0.41, p < 0.01; trachea: cc = -0.51, p < 0.01;*: p < 0.05 Nasal2 vs. Nasal1, paired t-test).

| ROI       | NHF 15 L/min | NHF 30 L/min | NHF 45 L/min |
|-----------|--------------|--------------|--------------|
| Nasal1    | 0.70 (0.26)  | 0.53 (0.17)  | 0.39 (0.11)  |
| Nasal2    | 0.91 (0.34)* | 0.69 (0.24)* | 0.48 (0.11)* |
| Pharynx   | 7.80 (2.96)  | 6.19 (3.82)  | 4.43 (2.92)  |
| Trachea   | 23.73 (6.63) | 14.30 (13.43)| 10.53 (9.85) |
| Patient | Baseline | NHF 15 L/min | Baseline | NHF 30 L/min | Baseline | NHF 45 L/min |
|---------|----------|--------------|----------|--------------|----------|--------------|
| A       |          |              |          |              |          |              |
| Tidal volume (mL) | 332.0 | 282.6 | 348.7 | 300.4 | 331.5 | 191.7 |
| Respiratory rate (min⁻¹) | 10.9 | 12.2 | 12.3 | 10.6 | 12.3 | 10.8 |
| Minute ventilation (L/min) | 3.6 | 3.4 | 4.3 | 3.2 | 4.1 | 2.1 |
| SpO₂ (%) | 96.1 | 96.4 | 96.8 | 96.6 | 96.9 | 97.1 |
| Tissue CO₂ (mmHg) | 32.0 | 31.8 | 31.3 | 31.2 | 30.7 | 30.6 |
| B       |          |              |          |              |          |              |
| Tidal volume (mL) | 366.7 | 289.7 | 438.5 | 364.3 | 334.6 | 332.3 |
| Respiratory rate (min⁻¹) | 12.9 | 14.3 | 12.2 | 12.4 | 15.0 | 14.8 |
| Minute ventilation (L/min) | 4.7 | 4.1 | 5.4 | 4.5 | 5.0 | 4.9 |
| SpO₂ (%) | 92.6 | 92.2 | 92.9 | 92.8 | 93.5 | 94.6 |
| Tissue CO₂ (mmHg) | 48.2 | 49.1 | 48.0 | 48.7 | 48.7 | 48.3 |
| C       |          |              |          |              |          |              |
| Tidal volume (mL) | 290.1 | 264.1 | 333.0 | 255.6 | 391.1 | 247.6 |
| Respiratory rate (min⁻¹) | 14.1 | 13.2 | 12.2 | 12.1 | 14.0 | 12.3 |
| Minute ventilation (L/min) | 4.1 | 3.5 | 4.1 | 3.1 | 5.5 | 3.0 |
| SpO₂ (%) | 96.6 | 96.5 | 97.4 | 97.6 | 97.0 | 97.0 |
| Tissue CO₂ (mmHg) | 39.2 | 38.5 | 41.2 | 40.0 | 38.3 | 37.8 |

Table 3: Change of ventilation parameters, peripheral capillary oxygen saturation (SpO₂) and tissue CO₂ in three patients participating in the study by NHF 15, 30 and 45 L/min during measurement of tracheal gases. All patients had normal respiratory rate and relatively small tidal volume assessed with calibrated respiratory inductance plethysmography.
Figure captions

Figure 1: Lateral gamma camera image of nasal $^{81m}$Kr-gas inhalation overlaid on the coronal MRI image of a volunteer during breath holding. A) Definition of anterior (Nasal1), posterior (Nasal2), pharyngeal, tracheal and lung ROIs. B) Visualization of $^{81m}$Kr-gas distribution 500 ms after the application of NHF at a rate of 45 L/min (right) in comparison to the control (left) shows fast clearance of the tracer gas in the upper airways. The control measurement without cannula flow shows stable $^{81m}$Kr-gas concentration.

Figure 2: $^{81m}$Kr-gas clearance half-times of the anterior (Nasal1) and posterior (Nasal2) nasal cavity (A) and in the pharyngeal and tracheal space (B) during NHF rates of 15, 30 and 45 L/min. This figure demonstrates flow-dependent clearance (Nasal1 vs. NHF: cc = -0.55, p < 0.01; Nasal2 vs. NHF: cc = -0.57, p < 0.01) that was always faster in the Nasal1 ROI than in the Nasal2 ROI, which shows a direction of clearance. Data are mean +/- SD; *: p < 0.05, paired t-test.

Figure 3: A) Tracheal CO2 concentration plotted against inspired volume of a single breath of a tracheotomized patient demonstrates a decrease of CO2 re-breathing during an NHF rate of 45 L/min. B) Tracheal O2 concentration plotted against inspired volume illustrates an increase of O2 in the inspired gas during NHF. Both curves of inspired CO2 and O2 demonstrate maximum differences in the concentration of the gases within the first 0.1 L (100 mL) of inspired volume.

Figure 4: Effect of NHF rates at 15, 30 and 45 L/min on the total inspired tracheal CO2 (A) and inspired O2 (B) in the first 100 mL of inspired volume in three patients who are individually represented in the graphs, where the three symbols represent the three NHF rates applied. The data in this figure is presented as means calculated from 2-minute intervals. An increase of NHF from 15 to 45 L/min led to a flow-dependent reduction of inspired CO2 and a rise of
inspired O₂. C) Relation between change (Δ) of total inspired O₂ vs. CO₂ in the first 100 mL per breath with linear regression ($r^2 = 0.59$) and 95% confidence intervals. This figure demonstrates that there is a significant correlation between the reduction of CO₂ and the increase of O₂ by means of NHF therapy ($cc = -0.767, p = 0.016$). D) Ratio of inspired CO₂ in the first 100 mL of tidal volume to the total inspired CO₂ per breath during baseline ventilation and during NHF (15, 30 and 45 L/min; ratio = 0.84 (SD 0.10) vs. 0.75 (SD 0.12) for baseline measurements; $p < 0.01$).
